Innoviva, Inc. (INVA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$22.25
Price Target
$32.50
Target Range
$17.00 — $46.00
Analyst Rating
Buy
Forward P/E11.3x
Trailing P/E6.7x
Forward PEG1.10
Implied Growth-38.1%
Median Target$33.50
Analyst Spread89.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$17
-23.6%
Consensus
$33
+46.1%
Bull Case
$46
+106.8%
Valuation Model TargetsConfidence: 35/100
Bear$1
Base$17
Bull$-13
INVA Price Target Analysis
Updated March 4, 2026As of March 4, 2026, Innoviva, Inc. (INVA) has a Wall Street consensus price target of $32.50, based on estimates from 10 covering analysts. With the stock currently trading at $22.25, this represents a potential upside of +46.1%. The company has a market capitalization of $1.66B.
Analyst price targets range from a low of $17.00 to a high of $46.00, representing a 89% spread in expectations. The median target of $33.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, INVA trades at a trailing P/E of 6.7x and forward P/E of 11.3x. The forward PEG ratio of 1.10 indicates reasonable valuation for growth. Analysts expect EPS to grow -38.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $16.57, with bear and bull scenarios of $0.83 and $-12.68 respectively. Model confidence stands at 35/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+92.5%
Avg Forward P/E24.5x
Peers with Coverage5 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| INVAInnoviva, Inc. | $1.7B | $22.25 | $32.50 | +46.1% | Buy | 11.3x | 10 |
 RPRXRoyalty Pharma plc | $7.1B | $47.26 | $49.40 | +4.5% | Buy | 9.7x | 11 |
 LGNDLigand Pharmaceuticals Incorporated | $4.0B | $202.09 | $248.00 | +22.7% | Buy | 23.8x | 16 |
 BTXBlackRock Technology and Private Equity Term Trust | $765M | $6.55 | — | — | — | — | — |
 XOMAPXOMA Corporation | $321M | $26.06 | — | — | Buy | 39.1x | 9 |
 XOMAXOMA Royalty Corp. | $305M | $25.54 | $68.25 | +167.2% | Buy | 38.3x | 10 |
 CBUSCibus, Inc. | $106M | $3.57 | $11.50 | +222.1% | Buy | — | 3 |
 CDTCDT Equity Inc. | $30M | $0.60 | — | — | — | — | — |
Upside Potential Comparison
CBUSXOMAINVALGNDRPRXSee INVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INVA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INVA vs AGIO
See how INVA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
What is the INVA stock price target for 2026?
The consensus Wall Street price target for INVA is $32.5, representing 46.1% upside from the current price of $22.2475. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is INVA a buy, sell, or hold?
INVA has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $32.5 implies 46.1% upside from current levels.
Is INVA stock overvalued or undervalued?
With a forward P/E of 11.3046x, INVA trades at a relatively low valuation. The consensus target of $32.5 implies 46.1% appreciation, suggesting meaningful undervaluation.
How high can INVA stock go?
The most bullish Wall Street analyst has a price target of $46 for INVA, while the most conservative target is $17. The consensus of $32.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $-13 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover INVA stock?
INVA is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the INVA stock forecast?
The 12-month INVA stock forecast based on 10 Wall Street analysts shows a consensus price target of $32.5, with estimates ranging from $17 (bear case) to $46 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $17, with bear/bull scenarios of $1/$-13.
What is INVA's fair value based on fundamentals?
Our quantitative valuation model calculates INVA's fair value at $17 (base case), with a bear case of $1 and bull case of $-13. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 35/100.
What is INVA's forward P/E ratio?
INVA trades at a forward P/E ratio of 11.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 6.7x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy INVA stock?
Wall Street analysts are very optimistic on INVA, with a "Buy" consensus rating and $32.5 price target (46.1% upside). 5 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do INVA price targets vary so much?
INVA analyst price targets range from $17 to $46, a 89% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $32.5 consensus represents the middle ground. Our model's $1-$-13 range provides an independent fundamental perspective.